In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

ITRS, a global provider of real-time IT observability solutions for financial services and other regulated industries, today announced a strategic partnership with the BSE (formerly Bombay Stock ...

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

Varaha is launching the Varaha Industrial Partners Program (VIPP), a global initiative that enables biomass processing ...

Applications are now open for the 2026 New Ventures BC Competition, presented by Innovate BC. The annual competition attracts BC's most promising early-stage startups for six months of mentorship, ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass executive Jeff Polashuk is exiting the company after eight years with the brokerage, The Real Deal has learned.

The new accreditation working group formed “to assess how legal education and licensure practices and processes can address the justice gap crisis and ensure public trust and confidence in the legal ...

This article is authored by Caroline Pendleton Nash, CEO, Queen Elizabeth's Global Schools.

At the end of the day, it's really the council speaking on behalf of the section that deals with the lion's share of issues that involve accreditation and gets the spotlight,” said Daniel Rodriguez, ...